Regeneron Pharmaceuticals, Inc.
Compare market positioning with top industry peers
Explore Regeneron Pharmaceuticals
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 1988 in Tarrytown, New York
Regeneron began in 1988 when Leonard Schleifer and George Yancopoulos built a company around serious disease biology and platform science rather than a single product idea.
George D. Yancopoulos has served as Regeneron's Chief Scientific Officer since 1989 and became board co-chair in 2023, making him one of the longest-serving scientific leaders in the biotechnology industry. Yancopoulos has personally led the development of the VelocImmune, VelociGene, and Veloci-8i2 platforms, which have produced 15 approved medicines and nearly 50 clinical candidates. He has published over 350 scientific papers and holds more than 100 patents covering antibody engineering, trap technologies, and genetic medicine approaches. Yancopoulos played the central scientific role in the discovery of EYLEA, Dupixent, Libtayo, Praluent, and Evkeeza, and he continues to oversee the Regeneron Genetics Center, which has sequenced over 3 million exomes. His 2024 compensation included a base salary of $1.3 million and total compensation of approximately $16 million, with significant equity awards tied to scientific milestones. Yancopoulos is known for attending late-night lab meetings and reviewing primary experimental data personally, maintaining a scientific presence that reinforces the company's culture of rigorous peer review.
Leonard S. Schleifer and George D. Yancopoulos founded Regeneron around a science-led model for discovering medicines for serious disease.
The company listed on Nasdaq and funded a long period of platform research before becoming a commercial biotech.
Arcalyst validated Regeneron's trap-technology work and showed that the platform could produce approved therapies.
EYLEA gave Regeneron a major ophthalmology franchise and moved the company into large-scale commercial operations.
Dupixent, developed with Sanofi, became a global immunology growth engine and a central part of Regeneron's collaboration economics.
Regeneron agreed to acquire Checkmate Pharmaceuticals for about $250 million to add the investigational TLR9 agonist vidutolimod.
Regeneron completed its acquisition of Decibel Therapeutics and added hearing-loss gene-therapy programs, including investigational DB-OTO in Phase 1/2 CHORD. It was not an approved therapy.
Regeneron acquired full development and commercialization rights to 2seventy bio's cell-therapy platforms and pipeline programs.
Regeneron reported FY2025 revenue of about $14.34 billion, with Dupixent growth offsetting pressure in the original EYLEA franchise.
Add investigational innate immune activation work for oncology combinations.
Expand genetic-medicine and hearing-loss programs.
Create Regeneron Cell Medicines and bring cell-therapy programs in-house.
Since its establishment in 1988, Regeneron Pharmaceuticals, Inc. expanded from an early-stage venture into a recognized leader in Biotechnology and pharmaceuticals, overcoming key market challenges.
Over its history, Regeneron Pharmaceuticals, Inc. executed decisive strategic pivots toward scalable monetization and digital distribution, securing its current market leadership.
By continually modernizing operations and embracing workflow automation, Regeneron Pharmaceuticals, Inc. maintains resilience through changing technological and economic cycles.